Abstract: Methods and compositions provide suitable support material for culturing cells with a desirable metabolic activity. For example, keratinocytes directly grown on flexible supports show metabolic activity. Therapeutic methods and compositions, including wound healing technologies, using the cells grown on flexible supports, wherein the cells exhibit increased metabolic activity are disclosed.
Abstract: The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent.
Type:
Grant
Filed:
October 24, 2012
Date of Patent:
February 25, 2014
Assignee:
Novozymes A/S
Inventors:
Preben Nielsen, Poul Erik Pedersen, Helle Outtrup
Abstract: The invention provides, biologically active spinosyns, hybrid spinosyn polyketide synthases capable of functioning in Saccharopolyspora spinosa to produce the spinosyns, and methods of controlling insects using the spinosyns.
Type:
Grant
Filed:
March 28, 2011
Date of Patent:
January 7, 2014
Assignee:
Dow AgroSciences, LLC.
Inventors:
Lesley S. Burns, Paul R. Graupner, Paul Lewer, Christine J. Martin, William A. Vousden, Clive Waldron, Barrie Wilkinson
Abstract: The present invention provides methods of producing isolated heat stable polypeptides by expressing the polypeptides in a prokaryotic host cell and subjecting the host cell to heat lysis. The invention further provides screening methods by producing a plurality of isolated heat stable polypeptides by expressing each of the plurality of polypeptides in a prokaryotic host cell and subjecting the host to heat lysis.
Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
Abstract: The present invention relates to novel subtilase variants exhibiting alterations relative to the parent subtilase in one or more properties including: Wash performance, thermal stability, storage stability or catalytic activity. The variants of the invention are suitable for use in e.g. cleaning or detergent compositions, such as laundry detergent compositions and dishwash compositions, including automatic dishwash compositions.
Type:
Grant
Filed:
April 29, 2013
Date of Patent:
October 29, 2013
Assignee:
Novozymes A/S
Inventors:
Tina Sejersgard Fano, Claus Von Der Osten, Malene Kappen Kruger, Mads Norregaard-Madsen
Abstract: The present invention relates to pectate lyase variants exhibiting alterations relative to a parent enzyme exhibiting pectate lyase activity as its major enzymatic activity; to a method of producing such enzymes; and to methods for using such enzymes in the textile, detergent and cellulose fiber processing industries. Compared to the parent enzyme, the pectate lyase variants of the present invention exhibit improved stability in detergents.
Type:
Grant
Filed:
September 6, 2012
Date of Patent:
October 22, 2013
Assignee:
Novozymes A/S
Inventors:
Sanne Schroder Glad, Carsten Andersen, Torben Vedel Borchert, Katja Salomon Johansen, Henrik Frisner, Mads Eskelund Bjornvad, Thomas Thisted
Abstract: The present disclosure relates to a method for reducing nuclease activity in a subtilisin solution obtained from a fermentation broth including: a) adjusting the pH of the subtilisin solution to a pH in the range of from pH 8.5 to pH 10.5; b) adding a polyol; and c) adjusting the temperature of the subtilisin solution to a temperature in the range of from 50° C. to 80° C. In accordance with the present disclosure, the nuclease activity is reduced to less than 5% of the initial value and the subtilisin activity is maintained at more than 60% of the initial value.
Type:
Grant
Filed:
August 19, 2008
Date of Patent:
October 15, 2013
Assignee:
Novozymes A/S
Inventors:
Kim Uhre Hansen, Peter Rahbek Oestergaard
Abstract: A polynucleotide encoding a modified luciferase polypeptide. The modified luciferase polypeptide has at least 60% amino acid sequence identity to a wild-type Oplophorus luciferase and includes at least one amino acid substitution at a position corresponding to an amino acid in a wild-type Oplophorus luciferase of SEQ ID NO:1. The modified luciferase polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the wild-type Oplophorus luciferase.
Type:
Grant
Filed:
May 3, 2010
Date of Patent:
October 15, 2013
Assignee:
Promega Corporation
Inventors:
Lance P. Encell, Keith V. Wood, Monika G. Wood, Mary Hall, Paul Otto, Gediminas Vidugiris, Kristopher Zimmerman
Abstract: The present invention relates to methods for producing variants of a parent TY145 subtilase and of a parent BPN? subtilase and to TY145 and BPN? variants having altered properties as compared to the parent TY145/BPN? subtilase.
Abstract: A medical device includes a base material having an immobilized fibrinolytic enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kDa). The medical device is formed from at least a base material. A fibrinolytic enzyme is immobilized on the base material. The fibrinolytic enzyme is stabilized with a dextran sulfate having a molecular weight of less than 40 (kDa).
Abstract: Methods for obtaining concentrated sugar solution from polysaccharide enriched biomass by contacting biomass with water and at least one nucleophilic base to produce a polysaccharide enriched biomass comprising a solid fraction and a liquid fraction and then contacting the solid fraction with saccharification enzyme consortium to produce a saccharification product comprising at least about 7 percent by weight sugars in 24 hours. The methods include optionally adding at least one additive selected from the group consisting of polyethylene glycols, fatty acid esters, fatty acid ethoxylates, nonionic surfactants derived from polyethoxylated sorbitan and a fatty acid, sodium lauriminodipropionate, sodium cocoamphoacetate, sodium tridecyl ether sulfate and a combination of these, such that enzyme loading of the saccharification enzyme consortium can be reduced.
Type:
Grant
Filed:
November 19, 2009
Date of Patent:
September 3, 2013
Assignee:
E I du Pont de Nemours and Company
Inventors:
Subramaniam Sabesan, Christina Jacy Spado
Abstract: Disclosed are a protein encoded by any one of nucleic acids (i) to (iv): (i) a nucleic acid having a base sequence of SEQ ID NO: 1; (ii) a nucleic acid encoding a protein having an amino acid sequence of SEQ ID NO: 2; (iii) a nucleic acid encoding a dragline protein and having a sequence identity of 90% or more with the nucleic acid (i); (iv) a nucleic acid which encodes a dragline protein and hybridizes with a complementary chain of the nucleic acid (i) under stringent conditions, and a silk thread containing the protein.
Abstract: The present invention relates to a method for producing a polypeptide comprising using a signal peptide, to nucleic acid constructs comprising a first nucleotide sequence encoding the signal peptide and a second nucleotide sequence encoding a polypeptide which is foreign to the first nucleotide sequence. Furthermore, it also relates to expression vectors and host cells comprising the nuclei acid construct.
Abstract: The present invention relates to phytases having at least 76% identity to a phytase derived from Hafnia alvei and comprises at least one modification in the amino acid sequence thereof. These phytase variants have modified, preferably improved, properties, such as, reduced protease sensibility, preferably they exhibit improved properties in respect of thermal performance, such as heat-stability (temperature stability, thermostability), steam stability, pelleting stability and/or temperature profile; and/or protease stability, in particular pepsin stability, pH profile, specific activity, substrate specificity, performance in animal feed (such as an improved release and/or degradation of phytate), susceptibility to glycation, and/or glycosylation pattern. The invention also relates to DNA encoding these phytases, methods of their production, as well as the use thereof, e.g., in animal feed and animal feed additives.
Type:
Grant
Filed:
May 16, 2012
Date of Patent:
August 13, 2013
Assignee:
Novozymes A/S
Inventors:
Soeren Flensted Lassen, Leonardo De Maria, Lars Kobberoee Skov, Esben Peter Friis, Tomoko Matsui, Allan Noergaard, Jesper Vind
Abstract: Fatty acid 13-hydroperoxide lyase proteins which have been modified with respect to a previously described guava 13-hydroperoxide lyase and the nucleic acid sequences encoding these proteins. Also, recombinant nucleic acid molecules for expressing the modified 13-hydroperoxide lyases and methods of using such lyases in the field of organic synthesis.
Abstract: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950. Also provided are methods and compositions related to the HCV variants. Further provided are methods of isolating, identifying, and characterizing multiple viral variants from a patient.
Type:
Grant
Filed:
March 5, 2010
Date of Patent:
August 6, 2013
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Chao Lin, Tara Kieffer, Christoph Sarrazin, Ann Kwong
Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.
Abstract: Prepared is an extract composition having an improved protein synthetic activity in a cell-free protein synthesis system using a mammalian cultured cell extract. An eukaryotic translation initiation factor and/or translational regulator are added to a cell-free protein synthesis system comprising an extract prepared from cultured mammalian cells and a template mRNA. These factors are one or more selected from the group consisting of eukaryotic translation initiation factors 4E (eIF4E), 2 (eIF2) and 2B (eIF2B), and eukaryotic translational regulator p97.
Abstract: The present invention pertains in general to Bromelain and particularly to the different active compounds contained in this complex mixture of proteins. The present invention provides recombinant expressed cysteine proteases, which are found in Bromelain. It has been found that the method for expression of the recombinant proteins is superior to the purification from Bromelain itself.
Type:
Grant
Filed:
August 8, 2008
Date of Patent:
April 2, 2013
Assignee:
Ursapharm Arzneimittel GmbH
Inventors:
Rolf Müller, Nora Luniak, Klaus Eschmann